Lacnotuzumab

DB14928InvestigationalProtein Based Therapies

Lacnotuzumab is under investigation in clinical trial NCT01643850 (MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)).

Mechanism: Pharmacologically active on Macrophage colony-stimulating factor 1
Curator reviewed
Code names: MCS110

Resolves to

Compound

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lacnotuzumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.